Corxel Pharmaceuticals closed a $287 million Series D1 financing to advance CX11, an oral small‑molecule GLP‑1 receptor agonist for obesity and type 2 diabetes. Investors included RTW Investments, Hengdian Group Capital, TCGX Crossover, SR One, RA Capital and HBM. Corxel reported Phase II topline showing ~9.7% body‑weight loss at 16 weeks and is running Phase II in the US and Phase III in China. The financing will scale global development and commercialization planning for an oral GLP‑1 competitor to injectable agents, underlining investor appetite for oral, lower‑cost alternatives in the booming cardiometabolic category.